Product Description
mRNA-6981 is an mRNA encoding for PD-L1. This new autoimmune development candidate is designed to augment cell surface expression of PD-L1 on myeloid cells to provide co-inhibitory signals to self-reactive lymphocytes. (Sourced from: https://www.sec.gov/Archives/edgar/data/1682852/000119312520280422/d134701dex991.htm)
Mechanisms of Action: PD-L1 Inhibitor
Novel Mechanism: No
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Moderna
Company Location: CAMBRIDGE MA 02139
Company CEO: Stéphane Bancel
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Hepatitis, Autoimmune
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|